Patient or Disabled Group
Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s
Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases
AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap
Truqap, AstraZeneca, Television, Faslodex, Malignant neoplasm of breast
Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring
Wegovy, Nordisk, LifeMD, Telemedicine, Access, CALR gene, Obesity, semaglutide, Adult
FDA decision on Stealth’s Barth syndrome drug delayed, again
United States Food and Drug Administration, 3-Methylglutaconic aciduria type 2, Decision, Elamipretide
FDA approves Abeonas skin disease cell therapy
ZEVASKYN, United States Food and Drug Administration, Hallopeau-Siemens Disease, Approved, Wounds – qualifier, gene therapy, Abeona, Treating
AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer
Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability
J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing
Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder
Guided by data, Mosaic licenses two cancer compounds from Astex
Astex, Spatial Mosaic, ASTX029, MDM2 Antagonist ASTX295
HR25: LifeSignals launches cardiac monitoring patch to compete with iRhythm, Philips
Preventive monitoring, Plaque (lesion), Philips, Heart, iRhythm, LifeSignals, Medical Devices